Last reviewed · How we verify
3 % Minoxidil lotion
3% Minoxidil lotion, marketed by Mae Fah Luang University Hospital, is a topical treatment for hair loss with a key composition patent expiring in 2028. The drug's market position is bolstered by its well-established mechanism and primary indication for hair loss, providing a clear therapeutic benefit. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | 3 % Minoxidil lotion |
|---|---|
| Sponsor | Mae Fah Luang University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- N-Acetyl-Cysteine for Treatment of AGA in Men (PHASE4)
- Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement (PHASE4)
- Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement (PHASE4)
- Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3 % Minoxidil lotion CI brief — competitive landscape report
- 3 % Minoxidil lotion updates RSS · CI watch RSS
- Mae Fah Luang University Hospital portfolio CI